On July 15, 2022 TME Pharma N.V., a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), reported that it has officially changed its corporate name from "NOXXON Pharma N.V." to "TME Pharma N.V." and the ticker symbol for the company’s common stock on the Euronext Growth Paris will change from "ALNOX" to "ALTME" (Press release, TME Pharma, JUL 15, 2022, View Source [SID1234626439]). Trading under the new name and ticker symbol will begin at the market opening on Tuesday, July 19, 2022. In addition to the new ticker ALTME, the ISIN will be amended from NL0012044762 to NL0015000YE1 on the share consolidation Ex-Date, July 28, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TME Pharma also announced the launch of its new corporate website that can be viewed on www.tmepharma.com.
Aram Mangasarian, CEO of TME Pharma, commented: "Over the last several years, our company has evolved into an oncology biotech with a clear focus on advancing approaches altering the tumor microenvironment – TME – where our technology has shown strong signs of efficacy. The name change to TME Pharma marks this successful transformation for our team and our stakeholders. Our strategy will prioritize and continue to support opportunities with the fastest path to approval. Following recently reported exceptional results in our glioblastoma program, we will focus our capabilities to successfully develop our lead asset NOX-A12 and reach this milestone in this indication first."
All shares of NOXXON Pharma N.V. will become shares in TME Pharma N.V. at parity with no actions needed from the company’s current shareholders.